GuidelineJournal of clinical lipidology
A clinician's guide to statin drug-drug interactions.
Guideline in Journal of clinical lipidology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03696940. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 160 citations in OpenAlex.
- Investigating Intestinal Transporter Involvement in Rivaroxaban Disposition through Examination of Changes in Absorption.Pharmaceutical research · 2021Pooled it
- Assessment of the Effect of Filgotinib on the Pharmacokinetics of Atorvastatin, Pravastatin, and Rosuvastatin in Healthy Adult Participants.Clinical pharmacology in drug development · 2022Trial
- Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters.European journal of clinical pharmacology · 2018Trial
- Results of a Doravirine-Atorvastatin Drug-Drug Interaction Study.Antimicrobial agents and chemotherapy · 2017Trial
- A rare rosuvastatin-clarithromycin interaction presenting with acute liver injury and delayed rhabdomyolysis.Indian journal of pharmacology · 2026Article
- Natural products as HMG-CoA reductase inhibitors (statins) for the management of non-communicable diseases.Inflammopharmacology · 2026Review
- Statins, Vitamin D, and Cardiovascular Health: A Comprehensive Review.Biomedicines · 2025Review
- Statin Therapy as a Preventive Strategy for Nephrolithiasis: A Review of Current Evidence.Cureus · 2025Review
- 25 years of lipid-lowering therapy: secular trends in therapy of coronary patients.Wiener klinische Wochenschrift · 2025Observational
- Cyclosporine A sterically inhibits statin transport by solute carrier OATP1B1.The Journal of biological chemistry · 2025Article
- Management of dyslipidaemia in patients with comorbidities-facing the challenge.European heart journal. Cardiovascular pharmacotherapy · 2025Review
- Avasimibe Abolishes the Efficacy of Fluvastatin for the Prevention of Cancer in a Spontaneous Mouse Model of Breast Cancer.International journal of molecular sciences · 2025Article
- Regulation of organic anion transporting polypeptide 1B1 transport function by concurrent phosphorylation and lysine-acetylation: A novel posttranslational regulation mechanism.Molecular pharmacology · 2025Article
- Pharmacological strategies for preventing post-stroke seizures and epilepsy.Frontiers in neurology · 2025Review
- Clinical Pharmacokinetics and Pharmacodynamics of Letermovir in Allogenic Hematopoietic Cell Transplantation.Clinical pharmacokinetics · 2024Review
- Incidence, characteristics, and risk factors of drug-associated muscle adverse reaction: a retrospective real-world study of inpatients.European journal of clinical pharmacology · 2024Article
- Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration.Clinical pharmacokinetics · 2024Article
- Construction and characterization of a humanizedActa pharmaceutica Sinica. B · 2024Article
- Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review.Journal of clinical medicine · 2024Review
- Muscular toxicity of colchicine combined with statins: a real-world study based on the FDA adverse event reporting system database from 2004-2023.Frontiers in pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The statins are widely used worldwide to reduce risk for cardiovascular events in both the primary and secondary prevention settings. Although generally quite safe, the statins can be associated with a variety of serious side adverse effects, including myalgia, myopathy, and changes in plasma enzymes of hepatic origin. Although rare, the most serious of these is rhabdomyolysis. Several drugs can interfere with the metabolism and disposal of the statins, thereby increasing risk for adverse events. It is important that clinicians treating patients with statins be aware of the potential for drug-drug interactions between each statin and specific other drugs and take measures to prevent them. The prediction of potential drug-drug interactions derives from basic pharmacokinetic principles. Certain drug interactions are predicted by measuring the effect of interacting drugs on blood plasma concentrations of the statin. Individual patient variations resulting in part from polymorphisms in the metabolizing enzymes confound some of these predictions. Based on these known effects, a new classification for predicting statin drug interactions is proposed. This report discusses likely prescription and nonprescription interactions as well as potential alternatives for special populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.